Current Report Filing (8-k)
June 15 2018 - 3:36PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
June 12, 2018
Diplomat Pharmacy, Inc.
(Exact Name of Registrant as Specified in its Charter)
Michigan
|
|
001-36677
|
|
38-2063100
|
(State or Other Jurisdiction of
|
|
(Commission File Number)
|
|
(IRS Employer
|
Incorporation)
|
|
|
|
Identification No.)
|
4100 S. Saginaw St.
Flint, Michigan 48507
(Address of Principal Executive Offices) (Zip Code)
(888) 720-4450
(Registrants Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
o
Item 5.07 Submission of Matters to a Vote of Security Holders.
At the annual meeting of shareholders of the Company held on June 12, 2018, shareholders elected the three Class I director nominees for three-year terms, ratified the appointment of BDO USA, LLP as the Companys independent registered public accounting firm for the year ending December 31, 2018, and approved (on an advisory basis) the Companys named executive officer compensation. The annual meeting proposals were described in detail in the Companys definitive proxy statement filed on April 30, 2018 with the Securities and Exchange Commission.
The results of the voting are shown below.
Proposal 1 Election of Directors
Class I Nominees
|
|
Votes For
|
|
Votes Withheld
|
|
Broker Non-Votes
|
|
David Dreyer
|
|
57,615,452
|
|
502,681
|
|
7,161,530
|
|
Philip R. Hagerman
|
|
57,626,789
|
|
491,344
|
|
7,161,530
|
|
Shawn C. Tomasello
|
|
57,615,491
|
|
502,642
|
|
7,161,530
|
|
Proposal 2Ratification of the Appointment of Independent Registered Public Accounting Firm
Votes For
|
|
Votes Against
|
|
Abstain
|
|
64,424,797
|
|
751,430
|
|
103,436
|
|
Proposal 3 Advisory Vote on Named Executive Officer Compensation
Votes For
|
|
Votes Against
|
|
Abstain
|
|
Broker Non-Votes
|
|
57,851,659
|
|
186,360
|
|
80,114
|
|
7,161,530
|
|
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Diplomat Pharmacy, Inc.
|
|
|
|
By:
|
/s/ Brian Griffin
|
|
|
Brian Griffin
|
|
|
Chief Executive Officer
|
Date: June 15, 2018
3
Diplomat Pharmacy (NYSE:DPLO)
Historical Stock Chart
From Apr 2024 to May 2024
Diplomat Pharmacy (NYSE:DPLO)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Diplomat Pharmacy Inc (New York Stock Exchange): 0 recent articles
More Diplomat Pharmacy, Inc. News Articles